Enhertu quickly lands at general hospitals in Korea
By Eo, Yun-Ho | translator Kim, Jung-Ju
23.02.02 17:09:50
가나다라
0
Lands at 20 medical institutions including SMC, SNUH, Severance, etc.
Generated code for Enhertu through emergency drug committee (DCs) meetings...whether the drug receives reimbursement listing will determine the prescription amount
According to industry sources, Enhertu (trastuzumab deruxtecan), AstraZeneca and Daiichi Sankyo Korea’s new antibody-drug conjugate drug for HER2-positive breast cancer have passed the drug committees (DCs) of 20 medical institutions in Korea, including Samsung Medical Center, Seoul National University Hospital, Sinchon Severance Hospital, Kangbuk Samsung Medical Center, and Chonnam National University Hwasun Hospital.
Most hospitals held an emergency DC meeting to generate a prescription code for Enhertu, suggesting the healthcare professional’s high interest in the drug.
T
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)